Introduction: Profiling volatile organic compounds in exhaled breath enables the diagnosis of several types of cancer. In this study we investigated whether a portable point-of-care version of an electronic nose (e-nose) (Aeonose, [eNose Company, Zutphen, the Netherlands]) is able to discriminate between patients with lung cancer and healthy controls on the basis of their volatile organic compound pattern.
Introduction
Lung cancer has a high mortality rate and is one of the most common cancers worldwide, causing approximately 9% of all cancer-related deaths. 1 In only 15% of newly diagnosed cases, however, is it being detected at an early stage. 1, 2 Early diagnosis could substantially prolong life expectancy. 1, 3 Because current diagnostic tools for lung carcinoma are either expensive or invasive and therefore not ideal for screening purposes, a low-cost, noninvasive handheld portable tool such as the electronic nose (e-nose) could be useful in clinical practice. 2 Screening and early detection of cancer are prominent in the WHO cancer diagnosis and treatment program. For lung cancer, the National Lung Screening Trial (NLST) demonstrated a 6.7% improvement of overall survival and a 20% reduction in mortality for patients screened with computed tomography (CT). 4 A known disadvantage of screening programs is falsepositive results, which lead to high cost, concerns for the patient, and possible adverse events in follow-up investigations. 4 E-nose technology using the Aeonose has proved its ability to detect cancer. 5, 6 Lung cancer could also be detected from exhaled-breath analysis, for example, by using an e-nose, which is a new diagnostic tool for volatile organic compound (VOC) pattern analysis. VOCs are present in feces, urine, and exhaled breath; they are a product of metabolic processes, including cancer metabolism. 7 These compounds interact with specific sensors in the Aeonose and influence the conductance, thereby producing a specific profile. With an artificial neural network (ANN), the data can be analyzed and prepared for pattern recognition. The VOC patterns detected by e-nose technology could then be used in diagnosing a variety of diseases such as lung cancer. 5, [8] [9] [10] [11] Various studies report the use of this tool for VOC pattern analysis to detect lung malignancies, demonstrating fairly high diagnostic accuracies. [12] [13] [14] [15] [16] [17] [18] Yet, no large-scale implementation studies using an e-nose have been reported. One reason for the absence of blinded studies in the literature could be the reproducibility of apparently similar sensors used in different e-nose devices. 19 There appears to be an intersensor difference that is mainly due to small differences in the sensing layer and the absence of accurate temperature control. 19 Reproducibility would be improved if VOC patterns could be compared without building a new model for each device, thus enabling large-scale application. Another impediment to reproducibility could lie in the statistic or mathematical methods used to detect VOC patterns in exhaled breath. 2 These methods could compensate for the interdevice differences. 20, 21 This feasibility study investigated the added value of implementing an e-nose in diagnosing lung carcinoma. We used an ANN for VOC pattern recognition in differentiating patients with benign conditions from patients with lung malignancies. In contrast to other studies, we used an Aeonose (eNose Company, Zutphen, the Netherlands) with thermocycled metal oxide sensors.
Five similar e-noses were used interchangeably. The aim was to create a model for detecting lung cancer and validate it with a blinded set. The model calibrated with these devices could then be applied to numerous other e-nose devices without requiring new calibration.
Materials and Methods

Participants
Patients with histologically proved primary lung cancer and patients who visited the ear, nose, and throat (ENT) department for benign conditions, who are henceforth referred to as healthy controls, were recruited in a tertiary care referral hospital, Maastricht University Medical Centre. Exclusion criteria were age younger than 18 years and any treatment for current tumor or history of cancer. Tumor characteristics and medical history were collected from the patients' clinical records. TNM stage was noted according to version 7.0 of the American Joint Committee on Cancer guidelines. Both patients with SCLCs and NSCLCs were included. Information on current smoking habits and history of smoking was collected and reported in pack-years. Nonsmoking was defined as no smoking in the previous month. Any side or adverse effects during or shortly after measurement were documented. Measurements were performed at the outpatient clinic of the ENT and lung department. Oral informed consent was obtained from all patients. The study protocol was approved by the medical ethics committee.
Materials
For this study, we used five Aeonoses 
Study Design
Before measurement, patients were instructed to gently inhale and exhale for five minutes through a disposable mouthpiece in the Aeonose. This mouthpiece contains a high-efficiency particulate arrestance filter that protects the device from contamination by bacteria and viruses. The patient's lips were to be closed over the mouthpiece at all times, and a nose clip was used to prevent nasal air passage. A short test run of inhalations and exhalations was performed so the patient could get acquainted with the device. Carbon filters were used to diminish the possibility that environmental VOCs would tamper with the measurement. For the first 2 minutes, the lungs were rinsed with clean filtered air that had passed through the carbon filters without passing the sensors, and dead air space was removed. Afterward, a valve was opened to ensure the passage of exhaled air over the sensors. The total measurement cycle lasted about 15 minutes, with the patient inhaling and exhaling into the device during 5 of those 15 minutes. The remaining time was used to measure any lowconcentrated VOCs inside the Tenax tube and to regenerate the sensors with clean filtered air (for details see van Hooren et al. 22 ). Performing these measurements did not influence the regular diagnostic work-up. Patients did not receive individual diagnostic results from the e-nose analysis. Both patients and healthy controls were divided into a training set and a blinded set for validation.
Statistical Analysis
Baseline group differences were determined by using the independent sample t test or Fisher's exact test. All statistical analyses were performed using IBM SPSS Statistics for Windows, version 22.0 (IBM Corp., Armonk, NY).
During one measurement, 64 times 36 data points were recorded for each sensor. To compress these data points of temperature, measurement cycle, and sensors, a Tucker3-like solution for tensor decomposition was used. 23 The resulting vectors of the compressed information were used as input for an ANN. The data compression and ANN have been integrated in a proprietary software package (Aethena [eNose Company, Zutphen, the Netherlands]). ANN training was executed for a number of data scaling options and network topologies, resulting in multiple ANN options for separating benign from malignant conditions. Part of the data was premarked as either benign or malignant to train the ANN. Data were cross-validated by using the leave-10%-out method. This method prevents to a large extent the fitting of data on artifacts instead of VOC breath profile classifiers. After the training, the model created by the ANN was used to score the blinded set of patients with benign conditions or lung cancer. For more details of the statistical analysis, see Kort et al. 24 As a rule of thumb, at least 20 patients and 20 controls are needed to create an ANN model. Because this model is based on pattern recognition, more measurements lead to improved robustness of the model.
The individual e-nose classification values are presented in a scatterplot and a receiver operating characteristic (ROC) curve, enabling choice of a sensitivityspecificity combination. For the training group, a threshold (range -1 to 1) was determined to obtain the best possible diagnostic accuracy. We report the sensitivity, specificity, area under the curve (AUC), negative predictive value (NPV), positive predictive value (PPV), and overall accuracy of the training set and the blinded set.
Results
Baseline Characteristics
Between May 2013 and January 2016, we included 107 patients with benign disease and 60 patients with histologically proved lung carcinoma. No adverse effects were observed when using the Aeonose. The ANN was trained with measurements from 52 patients with lung cancer and 93 healthy controls. The remaining measurements (from 14 healthy controls and 8 patients with lung cancer) were used for the blinded validation set. A cohort flowchart is presented in Figure 1 (left column), and baseline characteristics are given in Table 1 . No significant baseline differences were found for age, pack years, or currently smoking.
Data Analysis
For each patient the model calculated an individual value between -1 and 1, with -1 meaning benign and 1 meaning malignant. To obtain the best possible diagnostic accuracy of this set, a threshold of -0.70 was imposed. Patients with values greater than that level were scored as positive for lung cancer and those with values less than -0.70 were scored as negative.
The individual classification of all patients with lung cancer and healthy controls in the training set are presented in a scatter plot (Fig. 2) . Analysis of these data revealed a sensitivity of 83% and a specificity of 84%, with an overall accuracy of 83% in differentiating patients with lung cancer from healthy controls. The ROC curve of the cross-validation data is plotted in Figure 3 . The model of the training set has an AUC of 0.84. Figure 4 shows the individual classification values of the blinded validation set. Two false-positive and one false-negative result were identified. This reveals a sensitivity of 88%, a specificity of 86%, a PPV of 0.78, a NPV of 0.92, and an overall accuracy of 86%. The results for both the training set and the blinded set are shown in Figure 1 (right column).
Discussion and Conclusion
Over the past few years numerous studies have examined the use of VOCs for diagnosing lung cancer. The main detection technique is gas chromatography-mass 
spectrometry (GS-MS). GS-MS is able to detect
VOCs at the level of their chemical structure, but it requires skilled personnel and is expensive and time-consuming. Furthermore, more than one VOC has been found for lung cancer. Saalberg et al. provided a good summary of the various VOC biomarkers for lung cancer, noting that 33 different VOCs were reported in more than one study. 25 This limits the diagnostic value of the VOC biomarkers found by GS-MS.
The e-nose technology as used in this study is based on pattern recognition, and therefore, the device needs to be trained. Accordingly, the accuracy of this method depends on the size of the training set, representativeness of the sample population, and reliability of the criterion standard (e.g., biopsy). After external validation, the model created by the ANN can be used by other e-nose devices without the need for a new training set. An advantage for the practitioner is that the handheld e-nose used in this study (Aeonose) is quick to administer, easy-to-use in the outpatient clinic, and low-cost. An advantage for the patients is that it is noninvasive, they do not have to interrupt their smoking behavior, and they are allowed to eat and drink before the measurement. As a result, patients can be checked without interruption of their daily routine and without any specific preparations. In the near future, this device will also be able to provide a classification within seconds after completing the measurement. This is a unique feature of the e-noses used in this study. In fact, the newest version of the Aeonose has the technology onboard for online classification. 
May 2018 Electronic Nose for Lung Cancer Screening
Using e-nose technology, Gasparri et al. found a sensitivity of 81% and a specificity of 91% when comparing 70 patients with lung cancer with 76 healthy controls. All patients followed a strict hygiene protocol; this meant no smoking the night before the measurement, no food or drink (except water) in the previous 8 hours, and no perfume or scented soap in the preceding 24 hours. 26 A study by D'Amico et al. used GS-MS and found a sensitivity of 85% and a specificity of 100%. 13 Rocco et al. found a sensitivity and specificity of 86% and 95%, respectively, when using e-nose technology. Patients were asked to breathe into a special cartridge, which was then sent to the laboratory for gas chromatography. 27 Phillips et al. investigated VOC profiles using GS-MS with 95 patients with histologically confirmed lung cancer and 82 controls; they added a blinded control set and obtained similar results. 11 Shlomi et al. found a sensitivity and specificity of 75% and 93.3%, respectively, when using nanoarray sensors with cartridges. VOC analysis took place in a laboratory. All patients and controls followed a hygiene protocol, and the results were not compared with a blinded validation set. This study was also able to distinguish patients with EGFR mutation from those with wild-type lung cancer.
17 Table 2 provides an overview of the aforementioned articles. 28 The e-nose technology has demonstrated its potential as an additional screening tool to use in existing screening programs for lung cancer. Of the total number of patients included in the NLST screening group who had positive outcomes, 96.4% had a false-positive result. In the NLST the overall PPV for positive screening results was 3.8%. 4 Furthermore, 24% of the surgical interventions were performed for benign diseases. The risk of death from radiation-induced lung cancer was estimated at 1 to 3 per 10,000 people screened. For females the authors estimated 0.3 new deaths from breast cancer per 10,000. 4 In the future, a prospective trial combining low-dose CT imaging and e-nose technology could lead to a major reduction of false-positive results and thus reduction of overdiagnosis.
This feasibility study investigated whether five portable handheld e-noses could distinguish between breath samples of patients with lung cancer and breath samples of healthy controls. A single blinded set consisting of both healthy controls and patients with lung cancer was added for validation of the ANN model. In this study, we found a high sensitivity and specificity when using e-nose technology to compare healthy controls with patients with lung cancer. The results in the training and blinded sets were comparable, confirming the reliability of the model described in this article. The high NPV (92% in the blinded set) suggests the added value of embedding e-nose to the armamentarium as an additional screening tool for lung cancer detection.
Limitations
This study compared patients with histologically confirmed lung cancers with healthy controls who had been selected for benign elective ENT surgery. These healthy controls did not receive special checkups to exclude a possible lung malignancy.
Our patient group consisted mainly of patients with a stage III or IV tumor, which for screening purposes is not desirable. However, as Phillips et al. found when using GS-MS, tumor mass affected serum levels of VOC markers but did not affect the abundance of VOC biomarkers. 28 A follow-up study enrolling more patients with stage I and stage II tumors is needed to investigate whether these early-stage tumors can indeed be detected.
Conclusion
E-nose technology is a promising tool for detecting lung cancer quickly in a noninvasive way. This study used a control group for validation of the models created by the ANN. A sensitivity of 83% and a specificity of 84% was found with 52 patients with lung cancer and 93 healthy controls. The blinded validation set showed comparable results. Other applications should be explored to improve the diagnostic value of e-nose technology, such as combination with low-dose CT with the aim of reducing the false-positive rates of CT and lowering overdiagnosis and overtreatment.
